Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

IntroductionCombining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically “cold” tumors, which are typically less responsive to immunotherapy, are characterized b...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alexander A. Pieper, Luke M. Zangl, Dan V. Speigelman, Arika S. Feils, Anna Hoefges, Justin C. Jagodinsky, Mildred A. Felder, Noah W. Tsarovsky, Ian S. Arthur, Ryan J. Brown, Jen Birstler, Trang Le, Peter M. Carlson, Amber M. Bates, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Amy K. Erbe, Paul M. Sondel, Ravi B. Patel, Zachary S. Morris
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	In situ vaccine cold tumor models OX40 agonist CpG – oligonucleotides radiation therapy radioimmunotherapy Immunologic diseases. Allergy RC581-607
Accès en ligne:	https://doaj.org/article/3c1a8a46c1f247d4b0ac7ee7662a9e57
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

Documents similaires